meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En     Fr

Our approach
   
insufficient data

Interactive explorer of NMA results

Risk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcorticosteroidsRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNremdesivirRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNconvalescent plasma treatmentRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNbaricitinibRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNtofacitinibRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcasirivimab/imdevimab (Ronapreve)Risk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNinterferonRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNtocilizumab Risk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNsarilumabRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcontroldirect evidencenetwork meta-analysis ROB:highsome concernslowNA

Click on treatment name to display related network evidence

T vs. C corticosteroidsremdesivirconvalescent plasma treatmentbaricitinibtofacitinibcasirivimab/imdevimab (Ronapreve)interferontocilizumab sarilumabcontrol
corticosteroids---NANANANANANANANANA
remdesivirNA---NANANANANANANANA
convalescent plasma treatmentNANA---NANANANANANANA
baricitinibNANANA---NANANANANANA
tofacitinibNANANANA---NANANANANA
casirivimab/imdevimab (Ronapreve)NANANANANA---NANANANA
interferonNANANANANANA---NANANA
tocilizumab NANANANANANANA---NANA
sarilumabNANANANANANANANA---NA
controlNANANANANANANANANA---

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons